Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 88,802
  • Shares Outstanding, K 106,146
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,140 K
  • EBIT $ -25 M
  • EBITDA $ -25 M
  • 60-Month Beta 0.99
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.28
  • Most Recent Earnings $-0.10 on 11/12/25
  • Next Earnings Date 03/06/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8100 +9.37%
on 02/05/26
1.3000 -31.85%
on 01/22/26
-0.0789 (-8.18%)
since 01/06/26
3-Month
0.8100 +9.37%
on 02/05/26
1.3000 -31.85%
on 01/22/26
-0.1241 (-12.29%)
since 11/06/25
52-Week
0.3258 +171.92%
on 06/06/25
1.5100 -41.33%
on 09/29/25
+0.0910 (+11.45%)
since 02/06/25

Most Recent Stories

More News
Stocks in play: Oncolytics Biotech Inc

Announced that the U.S. Food and Drug Administration has granted Fast Track Designation to pelareorep ...

ONCY : 0.8859 (+5.89%)
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population Company to launch controlled study in second-line KRAS-mutant...

ONCY : 0.8859 (+5.89%)
Record $2.5B Sector Start Spotlights Clinical Oncology Plays

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is surging toward $668.26 billion by 2034 with an 11.50% CAGR as innovative...

ALLO : 1.6900 (+3.68%)
ONCY : 0.8859 (+5.89%)
IMNM : 24.88 (+3.67%)
LLY : 1,058.18 (+3.66%)
KURA : 7.83 (+5.81%)
AMGN : 384.32 (+4.49%)
Hard-to-Treat Cancers: How 2026’s Top Clinical Platforms Are Beating Industry Benchmarks

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is charging toward a massive $668 billion valuation by 2034[1], fueled by a...

ONCY : 0.8859 (+5.89%)
FHTX : 5.68 (+8.60%)
ORIC : 10.42 (+4.62%)
LLY : 1,058.18 (+3.66%)
GOVX : 2.67 (+3.49%)
SLS : 3.73 (+5.67%)
Stocks in play: Oncolytics Biotech Inc

Today announced the voting results from its Special Meeting of Shareholders held on Thursday, January ...

ONCY : 0.8859 (+5.89%)
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

SAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“ Oncolytics ” or the “ Company ”), a clinical-stage immunotherapy company developing pelareorep, today...

ONCY : 0.8859 (+5.89%)
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The genomics in cancer care market is on a massive tear, projected to hit $69.16 billion by 2032 as doctors...

ONCY : 0.8859 (+5.89%)
BCT.TO : 5.70 (-0.52%)
ACRV : 1.6700 (+4.37%)
LLY : 1,058.18 (+3.66%)
BCTX : 4.18 (+0.24%)
GLSI : 29.00 (+15.13%)
CATX : 4.71 (+1.73%)
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced...

ONCY : 0.8859 (+5.89%)
CGON : 50.36 (+2.36%)
TAK : 17.89 (+0.51%)
Stocks in play: Oncolytics Biotech Inc

Announced updated clinical data from GOBLET Cohort 4 in patients with third-line metastatic squamous ...

ONCY : 0.8859 (+5.89%)
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR  Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with...

ONCY : 0.8859 (+5.89%)

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 1.0081
2nd Resistance Point 0.9573
1st Resistance Point 0.9216
Last Price 0.8859
1st Support Level 0.8351
2nd Support Level 0.7843
3rd Support Level 0.7486

See More

52-Week High 1.5100
Fibonacci 61.8% 1.0576
Fibonacci 50% 0.9179
Last Price 0.8859
Fibonacci 38.2% 0.7782
52-Week Low 0.3258

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar